Rheumatoid Arthritis with a Baby on Board? Exploring Treatment Options for Women of Childbearing Age is organized by Prime Education, LLC.
Release Date: April 10, 2019
Expiration Date: April 09, 2020
Physicians, Nurse Practitioners, Physician Assistants, Pharmacists, Nurses, and Case Managers
Continuing Education Credits:
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Physician Credit Designation Statement
PRIME® designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistant Accreditation Statement
This program has been reviewed and is approved for a maximum of 1.25 hours of AAPA Category I CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity.
Nurse Practitioner Accreditation Statement
This activity is approved for 1.25 contact hours of continuing education (which includes 1.25 hour of pharmacology) by the American Association of Nurse Practitioners.
Pharmacist Accreditation Statement
This curriculum has been approved for 1.25 contact hours (0.125 CEUs) by PRIME®
Nurse Accreditation Statement
PRIME® designates this activity for 1.25 contact hours.
Case Manager Accreditation Statement
The Commission for Case Manager Certification designates this educational activity for 1.25 contact hours for certified case managers. Credits for this program are pre-approved.
Pregnant or lactating women with rheumatoid arthritis (RA) have historically been considered a difficult-to-treat population due to limited treatment options and unaddressed safety concerns. However, recent clinical trials and real-world data are shedding light on the safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) for this unique patient population. What do these findings mean for managed care decision-making? Listen to this recording to hear a panel of renowned experts in RA, maternal fetal medicine, and managed care pharmacy untangle the evidence and address pressing questions faced by patients, providers, and payers in the setting of pregnancy.
Top reasons to listen:
• Learn what new evidence in RA treatment for women of childbearing age means for your organization
• Engage in collaborative problem-solving to optimize RA decisions
• Ask the experts your most pressing questions